Jala-ML Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, making it beneficial in managing asthma and allergic rhinitis. The synergistic action of these agents offers comprehensive control of allergic manifestations by targeting multiple inflammatory pathways. Jala-ML Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic urticaria, and as an adjunct therapy in asthma management to improve respiratory symptoms and enhance quality of life. It is generally well-tolerated, with minimal sedative effects due to Levocetirizine’s selective action. Dosage and duration should be as prescribed by a healthcare professional, considering patient-specific factors. Caution is advised in patients with hepatic or renal impairment. This combination therapy provides a convenient and effective option for patients requiring dual-action allergy management.